Gilead to buy cancer drugmaker Immunomedics for $21 billion
https://m.investing.com/news/stock-market-news/gilead-to-buy-immunomedics-in-a-21-billion-deal-2293952
(Reuters) -  Gilead Sciences Inc  (O:GILD) will acquire biopharmaceutical company  Immunomedics  Inc (O:IMMU) for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.The deal provides Gilead access to Immunomedics' breast cancer treatment drug, Trodelvy, which was granted an accelerated FDA approval in April.Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share, representing a premium of about 110% over their last closing price of $41.93 on Sept 11.